balovaptan Report issue

Small molecule Experimental

Active Ingredient History

NOW
  • Now
Balovaptan, is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of post-traumatic stress disorder.   Wikipedia

Chemistry

  • SMILES: CN1Cc2cc(Cl)ccc2-n2c(nnc2[C@H]2CC[C@H](Oc3ccccn3)CC2)C1
  • InChIKey: GMPZPHGHNDMRKL-RZDIXWSQSA-N
  • Mol. Mass: 409.92
  • ALogP: 4.37
  • ChEMBL Molecule:
    balovaptan  
More Chemistry

Pharmacology

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Autism Spectrum Disorder (Phase 3)

Healthy Volunteers (Phase 1)

Ischemic Stroke (Phase 2)

Stress Disorders, Post-Traumatic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue